[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
News and Views
April 1999

Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion

Author Affiliations

Drs Bunney (chair), Azarnoff, Brown, Cancro, Gibbons, Gillin, Hullett, Killam, Kupfer, Krystal, and Stolley are members of the Institute of Medicine Committee on the Efficacy and Safety of Halcion; Mr French and Dr Pope are staff members of the Institute of Medicine, Washington, DC. Dr Killam is deceased.

Arch Gen Psychiatry. 1999;56(4):349-352. doi:10.1001/archpsyc.56.4.349

Recent estimates indicate that there is a 10% prevalence of chronic insomnia in the adult population of the United States, with an associated annual cost of $90 to $107 billion.1 Since its approval in 1982 for use in the treatment of insomnia, an estimated 11 billion prescriptions for Halcion (triazolam) have been filled worldwide.2Halcion refers to the actual product that is manufactured and marketed by the Upjohn Co (hereinafter, Upjohn), Kalamazoo, Mich. Triazolam is the generic name of the pure active ingredient in Halcion. The committee uses the term Halcion in the text when it discusses clinical trials or events involving the actual product; otherwise, the committee uses the term triazolam.

First Page Preview View Large
First page PDF preview
First page PDF preview
×